Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy
| Autor: | William Small, Samar El Achy, Gehan A Khedr, Gayle E. Woloschak, I. Helenowksi, Jian Jun Wei, Germaine Gaber, Vamsi Parimi, Tamer Refaat, Eric D. Donnelly, Jonathan B. Strauss |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Uterine Cervical Neoplasms Gastroenterology 03 medical and health sciences 0302 clinical medicine Antigens Neoplasm Internal medicine Biomarkers Tumor medicine Humans 030212 general & internal medicine Carbonic Anhydrase IX Aged Cervical cancer Glucose Transporter Type 1 biology business.industry Cancer Chemoradiotherapy Middle Aged Hypoxia-Inducible Factor 1 alpha Subunit medicine.disease Ki-67 Antigen Treatment Outcome Oncology 030220 oncology & carcinogenesis Ki-67 Cohort biology.protein Adenocarcinoma Population study Female GLUT1 Tumor Suppressor Protein p53 business |
| Zdroj: | American Journal of Clinical Oncology. 44:58-67 |
| ISSN: | 0277-3732 |
| Popis: | PURPOSE/OBJECTIVE The objective of this study was to assess the association between pretreatment p53, hypoxia inducible factor 1a (HIF1a), Ki-67, carbonic anhydrase-9 (CA-9), and glucose transporter 1 (GLUT1) expression in locally advanced cervical cancer patients treated definitively with concurrent chemoradiation therapy (CRT) and treatment outcomes including overall survival (OS), progression-free survival (PFS), local-regional control (LC), and distant metastases-free survival (DMFS). PATIENTS AND METHODS Twenty-eight patients treated definitively and consecutively for cervical cancer with CRT had p53, HIF1a, Ki-67, CA-9, and GLUT1 protein expression assessed and scored semiquantitatively by 3 pathologists, blinded to the treatment outcomes. Outcomes were stratified by p53 (H-score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|